Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Agenus stock price, quote, forecast and news

AGEN
US00847G7051
A1JLKZ

Price

5.80
Today +/-
+0.29
Today %
+5.86 %
P

Agenus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Agenus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Agenus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Agenus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Agenus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Agenus Stock Price History

DateAgenus Price
8/23/20245.80 undefined
8/22/20245.47 undefined
8/21/20245.19 undefined
8/20/20244.95 undefined
8/19/20245.09 undefined
8/16/20245.28 undefined
8/15/20245.17 undefined
8/14/20244.58 undefined
8/13/20244.71 undefined
8/12/20245.13 undefined
8/9/20245.09 undefined
8/8/20245.28 undefined
8/7/20245.08 undefined
8/6/20245.43 undefined
8/5/20245.24 undefined
8/2/20245.63 undefined
8/1/20245.97 undefined
7/31/20246.04 undefined
7/30/20246.06 undefined
7/29/20246.49 undefined

Agenus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Agenus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Agenus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Agenus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Agenus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Agenus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Agenus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Agenus’s growth potential.

Agenus Revenue, EBIT and net profit per share

DateAgenus RevenueAgenus EBITAgenus Net Income
2029e590.99 M undefined0 undefined-63.19 M undefined
2028e445.98 M undefined-11.76 M undefined-72.26 M undefined
2027e333.63 M undefined-53.94 M undefined-102.52 M undefined
2026e143.24 M undefined-156.66 M undefined-170.25 M undefined
2025e128.93 M undefined-134.09 M undefined-207.56 M undefined
2024e128.88 M undefined-98.98 M undefined-220.55 M undefined
2023156.31 M undefined-160.11 M undefined-245.97 M undefined
202298.02 M undefined-180.24 M undefined-220.29 M undefined
2021295.67 M undefined37.23 M undefined-24.14 M undefined
202088.17 M undefined-116.01 M undefined-181.12 M undefined
2019150.05 M undefined-70.14 M undefined-107.87 M undefined
201836.78 M undefined-123.82 M undefined-159.9 M undefined
201742.88 M undefined-103.8 M undefined-120.9 M undefined
201622.57 M undefined-107.48 M undefined-127.2 M undefined
201524.82 M undefined-80.7 M undefined-88.08 M undefined
20146.98 M undefined-43.32 M undefined-42.69 M undefined
20133.05 M undefined-24.98 M undefined-33.23 M undefined
201215.96 M undefined-6.74 M undefined-12.12 M undefined
20112.76 M undefined-19.09 M undefined-24.07 M undefined
20103.36 M undefined-21.75 M undefined-22.7 M undefined
20093.33 M undefined-27.68 M undefined-31.11 M undefined
20082.65 M undefined-37.84 M undefined-31.59 M undefined
20075.55 M undefined-33.28 M undefined-38.73 M undefined
2006692,000 undefined-49.24 M undefined-52.67 M undefined
2005630,000 undefined-72.32 M undefined-74.89 M undefined
2004707,000 undefined-66.8 M undefined-56.95 M undefined

Agenus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000430000523321536242242361508829598156128128143333445590
--------25.00------60.0050.00--33.33650.00-80.00100.00300.00-8.3390.91-14.29316.67-41.33235.23-66.7859.18-17.95-11.72132.8733.6332.58
------75.0066.67-----100.00100.00100.00100.00100.0066.67100.00100.00----96.5998.9888.7898.08------
0000003200000233215262400008529287153000000
-3-3-4-9-18-26-41-57-66-66-72-49-33-37-27-21-19-6-24-43-80-107-103-123-70-11637-180-160-98-134-156-53-110
-------1,025.00-1,900.00-----660.00-1,850.00-900.00-700.00-950.00-40.00-800.00-716.67-333.33-486.36-245.24-341.67-46.67-131.8212.54-183.67-102.56-76.56-104.69-109.09-15.92-2.47-
-3-3-3-8-18-46-73-55-66-56-74-52-38-31-31-22-24-12-33-42-88-127-120-159-107-181-24-220-245-220-207-170-102-72-63
---166.67125.00155.5658.70-24.6620.00-15.1532.14-29.73-26.92-18.42--29.039.09-50.00175.0027.27109.5244.32-5.5132.50-32.7069.16-86.74816.6711.36-10.20-5.91-17.87-40.00-29.41-12.50
0.110.120.130.140.150.210.240.270.330.370.380.380.390.530.660.8111.181.492.993.914.354.925.546.758.6311.4514.0917.89000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Agenus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Agenus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
22.1746.4299.1460.8758.7387.9886.9261.7540.118.6834.4630.0719.7810.7521.4727.3540.22171.6776.4460.1953.0561.8199.87306.92193.3676.11
00.580.530.491.120.040.080.050.180.32000.0400.55009.811.351.130.9416.291.161.522.7425.84
00000000000000000000000000
000.671.370.970.230.170.250.440.510.230.320.030.020.0200.10.090.090.080.0600000
0.280.671.251.262.593.575.444.921.581.270.81.141.011.240.580.822.352.543.4412.1520.768.4412.7623.5317.0210.47
22.4547.67101.5963.9963.491.8292.666.9642.320.7835.4931.5320.851222.6128.1742.67184.191.3173.5574.8186.54113.78331.97213.12112.42
4.118.0314.6413.9311.3724.8524.9923.3518.6214.611.548.896.194.142.612.79615.3125.6326.1825.1233.6960.2791.08164.29163.03
00000000000000000000000000
00000000000000000000000000
0.0106.6410.59.077.966.865.754.643.532.431.3200006.7718.7616.3714.4112.3410.510.898.496.234.41
002.962.763.083.082.572.572.572.572.572.572.572.572.572.5717.8722.7922.3923.0522.9323.1925.4524.8825.4724.72
0.070.32.132.372.1412.376.045.524.823.044.81.561.291.11.31.31.221.271.281.211.211.424.129.544.459.34
4.198.3326.3729.5625.6648.2640.4537.1930.6523.7521.3414.3410.057.86.486.6631.8658.1365.6764.8561.5968.8100.73133.98200.43201.5
26.6456127.9793.5589.06140.08133.06104.1572.9544.5456.8245.8730.9119.8129.0934.8474.53242.23156.99138.4136.4155.33214.51465.96413.56313.91
00.210.270.290.330.40.460.460.460.480.670.91.120.220.250.360.630.860.881.0241.0828.328.882.573.063.94
00.090.20.230.290.380.440.440.440.450.510.540.570.580.60.640.720.850.870.951.011.061.261.521.641.79
-19.49-37.62-84.35-157.89-213.76-279.7-335.86-409.96-461.84-498.64-532.17-562.51-584.42-607.7-619.02-649.09-691.31-779.19-905.33-1,026.48-1,177.31-1,284.99-1,465.91-1,489.83-1,709.91-1,955.67
43.13-0.66-1.48-0.72-0.170.09-0.17-0.09-0.020000000-1.97-2.05-1.53-2.17-1.54-1.322.771.490.92-0.96
00000000000000000000000000
23.6451.68116.775.9277.76105.25106.4431.9-17.39-47.05-20.06-16.65-14.38-26.09-22.86-4.1623.0270.73-39.13-75.82-132.59-198.44-176.7634.44-61.28-160.33
2.040.432.272.951.443.182.922.591.090.670.540.90.70.810.640.841.714.495.438.0913.6213.5617.0230.4940.9461.45
0.050.9347.36811.310.8612.297.595.784.622.62.691.732.174.225.514.1727.8821.5724.5532.6831.0144.7240.247.87
0000020.010.140.261.781.691.721.892.021.811.730.7610.137.46.1429.7475.1780.2880.6899.28135.98
00000000000000000000000000
0.20.812.345.90.545.625.414.130.150.150.150.150.150.20.23.521.260.150.1520.640.150.791.581.068.5310.6
2.292.178.6116.219.9722.1119.219.159.088.3875.355.424.754.8110.39.2328.9440.8556.4468.06122.21129.88156.94188.95255.9
0.712.162.640.190.0110.254.5150.0475.3377.464.1349.4934.0532.7335.715.354.77114.33130.54142.3913.2113.3818.9513.1424.8517.49
00000000000000000000000000
000.011.221.322.482.93.065.935.816.0386.153.166.1723.6737.5128.2424.7215.4189.79224.17250.27247.97254.65188.91
0.712.162.651.411.3412.737.4153.1181.2783.2270.1657.4940.235.8941.8829.0242.28142.57155.26157.78203.01237.55269.21261.11279.51206.4
2.994.3311.2617.6211.3134.8326.6172.2590.3591.677.1562.8545.6140.6446.6939.3251.51171.5196.11214.22271.07359.76399.1418.05468.46462.3
26.6456127.9793.5489.06140.08133.06104.1572.9544.5557.0946.231.2314.5523.8435.1674.53242.23156.99138.4138.48161.32222.34452.49407.18301.96
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Agenus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Agenus's financial health and stability.

Assets

Agenus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Agenus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Agenus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Agenus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-8-18-46-73-56-66-56-74-51-37-30-30-21-23-11-30-42-87-127-120-162-111-182-28-230-257
0011456455544321011466676613
000000000000000000-500000000
01-11-3-4601-300-20-231-6610-60588-92410
015283521-80492769111213444439323738614231
000000001222110100111111113
000000000000000000000000000
-3-6-13-15-36-51-51-60-66-44-26-28-24-14-161-19-38-47-79-94-131-18-13910-175-224
0-3-4-2-1-2-18-3-200000000-2-3-12-3-3-4-3-33-53-9
0-3-4-12-39-523411513-429000-16-31172-3-4-4-43-333
00014-37-337441513-3210000-13-27305000-91913
000000000000000000000000000
0020-2-515-544200-20-6000-3107014-16202-10-8
718416705692540044618118102657111266863118022896128
7194266-151107474120342174792552189-2801283118322595119
00000000-1000000000-29-5020400-100
000000000000000000000000000
392449-35-403-817-9-99-40-9105-1110-65-11-7840192-113-101
-4.14-10.08-18.39-17.77-38.5-54.15-70.22-64.19-68.99-45.27-26.7-29.12-24.43-14.89-16.30.91-20.34-41.05-50.77-92.48-97.35-134.69-23.34-142.57-23.66-228.43-234.16
000000000000000000000000000

Agenus stock margins

The Agenus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agenus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agenus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Agenus's sales revenue. A higher gross margin percentage indicates that the Agenus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Agenus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Agenus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Agenus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Agenus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Agenus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Agenus Margin History

Agenus Gross marginAgenus Profit marginAgenus EBIT marginAgenus Profit margin
2029e98.01 %0 %-10.69 %
2028e98.01 %-2.64 %-16.2 %
2027e98.01 %-16.17 %-30.73 %
2026e98.01 %-109.37 %-118.85 %
2025e98.01 %-104 %-160.99 %
2024e98.01 %-76.8 %-171.13 %
202398.01 %-102.43 %-157.36 %
202289.22 %-183.88 %-224.73 %
202198.83 %12.59 %-8.16 %
202097.34 %-131.58 %-205.42 %
201998.01 %-46.74 %-71.89 %
201898.01 %-336.62 %-434.7 %
201798.01 %-242.09 %-281.96 %
201698.01 %-476.13 %-563.5 %
2015100 %-325.18 %-354.93 %
2014100 %-620.91 %-611.87 %
201382.4 %-820.36 %-1,091.36 %
201295.79 %-42.23 %-75.92 %
2011100 %-692.56 %-873.26 %
201096.34 %-647.41 %-675.51 %
2009100 %-830.2 %-933.05 %
2008100 %-1,427.54 %-1,191.66 %
200798.01 %-599.39 %-697.5 %
2006100 %-7,115.61 %-7,611.71 %
2005100 %-11,479.21 %-11,887.94 %
200499.29 %-9,448.37 %-8,055.45 %

Agenus Stock Sales Revenue, EBIT, Earnings per Share

The Agenus earnings per share therefore indicates how much revenue Agenus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Agenus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Agenus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Agenus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Agenus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Agenus Revenue, EBIT and net profit per share

DateAgenus Sales per ShareAgenus EBIT per shareAgenus Earnings per Share
2029e28.14 undefined0 undefined-3.01 undefined
2028e21.24 undefined0 undefined-3.44 undefined
2027e15.89 undefined0 undefined-4.88 undefined
2026e6.82 undefined0 undefined-8.11 undefined
2025e6.14 undefined0 undefined-9.88 undefined
2024e6.14 undefined0 undefined-10.5 undefined
20238.74 undefined-8.95 undefined-13.75 undefined
20226.96 undefined-12.79 undefined-15.64 undefined
202125.83 undefined3.25 undefined-2.11 undefined
202010.22 undefined-13.45 undefined-21 undefined
201922.23 undefined-10.39 undefined-15.98 undefined
20186.64 undefined-22.35 undefined-28.87 undefined
20178.71 undefined-21.09 undefined-24.57 undefined
20165.18 undefined-24.68 undefined-29.21 undefined
20156.35 undefined-20.63 undefined-22.52 undefined
20142.34 undefined-14.5 undefined-14.29 undefined
20132.05 undefined-16.79 undefined-22.33 undefined
201213.51 undefined-5.71 undefined-10.26 undefined
20112.77 undefined-19.18 undefined-24.19 undefined
20104.17 undefined-27.02 undefined-28.2 undefined
20095.07 undefined-42.07 undefined-47.28 undefined
20085.03 undefined-71.81 undefined-59.94 undefined
200714.31 undefined-85.77 undefined-99.81 undefined
20061.81 undefined-128.9 undefined-137.89 undefined
20051.66 undefined-190.31 undefined-197.09 undefined
20041.9 undefined-179.57 undefined-153.1 undefined

Agenus business model

Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus is one of the most popular companies on Eulerpool.com.

Agenus SWOT Analysis

Strengths

1. Strong Intellectual Property Portfolio: Agenus Inc. possesses a robust intellectual property portfolio which includes patents, trademarks, and copyrights. This helps protect their innovative technologies and provides a competitive advantage in the industry.

2. Diversified Product Pipeline: The company has a diverse pipeline of immunotherapies and vaccines targeting various types of cancer. This diverse portfolio reduces the risk associated with relying on a single product and expands the revenue potential.

3. Strategic Collaborations: Agenus Inc. has established strategic collaborations with leading pharmaceutical companies, which provides access to additional resources, expertise, and potentially lucrative partnership opportunities.

Weaknesses

1. Limited Financial Resources: Agenus Inc. may face challenges in funding its research and development activities due to limited financial resources. This could potentially limit the speed at which new products are developed and commercialized.

2. High Dependency on Partnerships: The company heavily relies on collaborations and partnerships for the development and commercialization of its products. Any failure or termination of these partnerships could negatively impact their business operations.

3. Lack of Established Products: Agenus Inc. currently does not have any approved products in the market. This puts them at a disadvantage compared to competitors who already have established products generating revenue.

Opportunities

1. Growing Demand for Cancer Treatments: With the increasing prevalence of cancer globally, there is a significant opportunity for Agenus Inc. to capitalize on the growing demand for effective cancer treatments. They can leverage their innovative immunotherapies to address this market need.

2. Advancements in Immunotherapy Research: Continuous advancements in the field of immunotherapy present opportunities for Agenus Inc. to further enhance their product portfolio and develop more targeted and effective treatments.

3. Expansion into Global Markets: Agenus Inc. can explore expansion opportunities in international markets where there is a growing demand for cancer treatments. This would allow them to tap into new customer bases and potentially increase their revenue streams.

Threats

1. Intense Competition: Agenus Inc. operates in a highly competitive industry with numerous pharmaceutical companies focusing on cancer treatments and immunotherapies. The intense competition can pose challenges in terms of market share and pricing pressures.

2. Regulatory Challenges: The regulatory landscape governing the development and approval of pharmaceutical products can be complex and lengthy. Regulatory challenges such as delays in approvals or stringent requirements may hinder the company's ability to bring products to market in a timely manner.

3. Technological Obsolescence: The rapid advancements in technology and scientific research pose a threat to Agenus Inc. The emergence of new treatment modalities or breakthroughs in cancer research could render their existing products or technologies obsolete.

Agenus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Agenus historical P/E ratio, EBIT, and P/S ratio.

Agenus shares outstanding

The number of shares was Agenus in 2023 — This indicates how many shares 17.894 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Agenus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Agenus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Agenus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Agenus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Agenus Stock splits

In Agenus's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Agenus.

Agenus latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.47 -2.52  (-71.27 %)2024 Q2
3/31/2024-3.28 -3.04  (7.33 %)2024 Q1
12/31/2023-1.07 -2.6  (-142.76 %)2023 Q4
9/30/2023-3.92 -3.2  (18.3 %)2023 Q3
6/30/2023-4.05 -4  (1.13 %)2023 Q2
3/31/2023-0.21 -0.22  (-2.71 %)2023 Q1
12/31/2022-0.22 -0.24  (-7.77 %)2022 Q4
9/30/2022-0.19 -0.19  (0.68 %)2022 Q3
6/30/2022-0.23 -0.17  (27.54 %)2022 Q2
3/31/2022-0.3 -0.19  (37.4 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Agenus stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

64

👫 Social

84

🏛️ Governance

38

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Agenus list of shareholders

%
Name
Stocks
Change
Date
7.55 % Deep Track Capital LP1,584,877012/31/2023
7.19 % The Vanguard Group, Inc.1,510,719166,42312/31/2023
6.74 % BlackRock Institutional Trust Company, N.A.1,414,399228,20712/31/2023
6.73 % Point72 Asset Management, L.P.1,413,406814,1462/20/2024
3.73 % Sofinnova Investments, Inc782,812114,57512/31/2023
3.72 % Invus Public Equities Advisors, LLC781,562012/31/2023
2.07 % State Street Global Advisors (US)434,013-612,46712/31/2023
2.00 % Millennium Management LLC419,148356,60212/31/2023
1.88 % Geode Capital Management, L.L.C.395,37839,63812/31/2023
1.44 % Renaissance Technologies LLC301,721270,70412/31/2023
1
2
3
4
5
...
10

Agenus Executives and Management Board

Dr. Garo Armen70
Agenus Chairman of the Board, Chief Executive Officer, Co-Founder (since 1994)
Compensation 5.63 M
Dr. Steven O'Day61
Agenus Chief Medical Officer
Compensation 1.31 M
Ms. Christine Klaskin57
Agenus Vice President - Finance
Compensation 628,125
Mr. Brian Corvese65
Agenus Independent Director
Compensation 589,503
Mr. Timothy Wright65
Agenus Lead Independent Director
Compensation 367,500
1
2
3

Agenus Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ginkgo Bioworks A Stock
Ginkgo Bioworks A
SupplierCustomer0,430,900,650,770,72-
UroGen Pharma Stock
UroGen Pharma
SupplierCustomer0,380,760,780,740,900,43
Incyte Stock
Incyte
SupplierCustomer0,190,59-0,03-0,320,080,02
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,09-0,37-0,79-0,80-0,41-0,32
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,080,57-0,84-0,75-0,87-0,42
Betta Pharmaceuticals A Stock
Betta Pharmaceuticals A
SupplierCustomer-0,06-0,730,900,820,800,38
Targovax Stock
Targovax
SupplierCustomer-0,090,830,320,660,920,49
Viatris Stock
Viatris
SupplierCustomer-0,17-0,58-0,330,380,570,31
Gilead Sciences Stock
Gilead Sciences
SupplierCustomer-0,180,10-0,380,520,570,38
Merck & Co Stock
Merck & Co
SupplierCustomer-0,45-0,64-0,93-0,84-0,54-0,31
1

Most common questions regarding Agenus

What values and corporate philosophy does Agenus represent?

Agenus Inc represents values of innovation, collaboration, and integrity in the biotechnology industry. With a dedication to advancing immune-oncology treatments, Agenus Inc focuses on discovering and developing breakthrough therapies for patients with unmet medical needs. The company's corporate philosophy emphasizes the importance of scientific excellence, ethical practices, and strong partnerships for achieving clinical success. Agenus Inc aims to revolutionize cancer treatment by harnessing the power of the immune system and developing personalized solutions. Through its cutting-edge research and commitment to improving patient outcomes, Agenus Inc remains a leading force in the biotech sector.

In which countries and regions is Agenus primarily present?

Agenus Inc is primarily present in the United States, as it is headquartered in Lexington, Massachusetts. The company operates across various states of the US, including California, New York, and Texas. In addition to its strong presence in the US, Agenus Inc also has a global reach with operations in several countries. These include Germany, the United Kingdom, Italy, Switzerland, and Japan, among others. Agenus Inc has established strategic partnerships and collaborations with organizations worldwide, further expanding its footprint and enhancing its presence in the biotechnology and pharmaceutical sectors.

What significant milestones has the company Agenus achieved?

Agenus Inc has achieved significant milestones throughout its journey. Notably, the company made advancements in immuno-oncology, specializing in the discovery and development of innovative cancer treatments. Key achievements include gaining FDA approvals for its proprietary vaccine, Prophage, in treating glioblastoma multiforme, a deadly brain cancer. Agenus Inc has also formed strategic partnerships with leading biopharmaceutical companies, enabling the development of novel checkpoint inhibitors and personalized cancer immunotherapies. By continuously pushing the boundaries of medical research and forging collaborations in the industry, Agenus Inc remains dedicated to revolutionizing cancer treatment and improving patient outcomes.

What is the history and background of the company Agenus?

Agenus Inc. is a biotechnology company specializing in the discovery and development of immunotherapies. Founded in 1994, the company has a strong history in the field of cancer research and has made significant contributions to the advancement of innovative treatment options. Agenus Inc. is known for its expertise in harnessing the power of the immune system to fight various types of cancer. With a diverse pipeline of potential immunotherapeutic candidates, the company strives to revolutionize cancer treatment and improve patient outcomes. Agenus Inc. continues to be a key player in the biotech industry, constantly pushing the boundaries of medical innovation.

Who are the main competitors of Agenus in the market?

The main competitors of Agenus Inc in the market include companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, and Novartis AG. These companies also operate in the biotechnology sector and compete with Agenus Inc in the development and commercialization of innovative immunotherapies and cancer treatments. Agenus Inc aims to differentiate itself by leveraging its unique proprietary technologies and immunology expertise to stay competitive in this rapidly evolving market.

In which industries is Agenus primarily active?

Agenus Inc is primarily active in the biotechnology industry. With a strong focus on immune oncology, the company develops innovative therapies and vaccines to combat cancer and other diseases. Agenus Inc's cutting-edge research and development initiatives aim to harness the power of the immune system to provide targeted treatment options. Their extensive portfolio includes a diverse range of immunotherapies, such as checkpoint inhibitors, personalized cancer vaccines, and antibody-based therapeutics. By leveraging their expertise in biotechnology, Agenus Inc strives to revolutionize healthcare by delivering novel solutions that have the potential to significantly improve patient outcomes in the fight against various diseases, particularly cancer.

What is the business model of Agenus?

Agenus Inc is a biotechnology company focused on the discovery, development, and commercialization of immune-based therapies for the treatment of cancer and other diseases. Their business model revolves around the development and licensing of innovative therapeutic antibodies, vaccines, and adjuvants, which help enhance the body's immune response to fight against various types of cancers. Agenus Inc aims to leverage its deep understanding of the immune system and advanced technologies to deliver breakthrough treatments with the potential to significantly improve patient outcomes. With its robust pipeline and strategic partnerships, Agenus Inc remains dedicated to advancing novel immunotherapies and revolutionizing the field of oncology.

What is the P/E ratio of Agenus 2024?

The Agenus P/E ratio is -0.47.

What is the P/S ratio of Agenus 2024?

The Agenus P/S ratio is 0.81.

What is the AlleAktien quality score of Agenus?

The AlleAktien quality score for Agenus is 6/10.

What is the revenue of Agenus 2024?

The expected Agenus revenue is 128.88 M USD.

How high is the profit of Agenus 2024?

The expected Agenus profit is -220.55 M USD.

What is the business model of Agenus

Agenus Inc. is a leading company in the field of precision medicine immunooncology. The company specializes in the identification, development, and marketing of innovative immunotherapies for the treatment of cancer. Agenus has a broad product pipeline that includes both immunotherapeutics and licensed products. The company operates in three main business areas: Discovery and Early Development, Clinical Development, and Commercial. Discovery and Early Development is the area where the company applies its scientific and technical expertise to the discovery and exploration of clinically investigated biologics. Products in this segment include antibodies against CTLA-4 and PD-1/PD-L1, as well as other immuno-oncology targets. Clinical Development is the business area where Agenus uses its clinical expertise to advance drug candidates through clinical trials in phases 1-3. Products in this segment include the immunotherapeutics Prophage, AutoSynVax, IMT-CRL, as well as a pipeline of innovative treatments. Commercial is the business area where the company introduces its products to the market. Agenus has entered into many partnerships and licensing agreements with other pharmaceutical and biotech companies to distribute its products worldwide. The company's flagship product is the CTLA-4 inhibitor, which was the first approved immunotherapy and is used for the treatment of melanoma. In addition, Agenus expects further FDA approvals of its products in 2021/22. Agenus combines immunotherapeutics with other treatment modalities, including surgery, radiation therapy, and chemotherapy, to enhance efficacy and combat side effects in cancer therapy. The company also has a pipeline of novel products in research and development, including stimulants, checkpoint inhibitors, and novel vaccine approaches. This pipeline brings Agenus closer to its goal of exploring and developing new and improved ways to treat cancer. Agenus also has a robust patent portfolio and utilizes its innovative QS-21 technology platform in its product development, which serves to enhance immunogenicity and immune response in vaccines. The company also has partnerships with other companies developing QS-21-licensed products for the treatment of oncological and infectious diseases. Overall, Agenus is a growing company that covers all aspects of biopharmaceuticals, including research, development, clinical trials, and marketing. The company is a pioneer in immunooncology and continues to strive for the development of innovative therapies that will contribute to improving treatment outcomes for cancer patients worldwide.

What is the Agenus dividend?

Agenus pays a dividend of 0 USD distributed over payouts per year.

How often does Agenus pay dividends?

The dividend cannot currently be calculated for Agenus or the company does not pay out a dividend.

What is the Agenus ISIN?

The ISIN of Agenus is US00847G7051.

What is the Agenus WKN?

The WKN of Agenus is A1JLKZ.

What is the Agenus ticker?

The ticker of Agenus is AGEN.

How much dividend does Agenus pay?

Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.

What is the dividend yield of Agenus?

The current dividend yield of Agenus is .

When does Agenus pay dividends?

Agenus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agenus?

Agenus paid dividends every year for the past 0 years.

What is the dividend of Agenus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agenus located?

Agenus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agenus from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Agenus pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Agenus in the year 2023?

In the year 2023, Agenus distributed 0 USD as dividends.

In which currency does Agenus pay out the dividend?

The dividends of Agenus are distributed in USD.

All fundamentals about Agenus

Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.